Medipattern Named Exclusive Canadian Distributor for SonoCine

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern" or the "Company") (TSX VENTURE:MKI),
a pioneer in the development of medical imaging software solutions that help
medical practitioners to better understand lesions and critical anatomy,
announced today that the Company is the exclusive distributor for SonoCine(R)'s
Automated Whole Breast Ultrasound System ("AWBUS") in Canada. AWBUS is used as
an adjunct to mammography for breast cancer screening. AWBUS automatically
acquires a sequence of ultrasound images which completely capture all of the
breast tissue as individually focused slices compared to mammography which
captures the breast in two compressed planes. SonoCine recently received
Canadian Medical Devices Conformity Assessment System (CMDCAS) approval from
Health Canada as a class II medical device and is available for immediate sales
in Canada. The first system will be installed this week at Clinique Radiologique
Audet in Quebec City. The product is offered on a capital purchase or a
fee-per-procedure basis. 


AWBUS, when used as an adjunct to mammography, was shown to detect 100 percent
more cancers as compared to mammography alone and is particularly effective for
women with dense breasts. Furthermore, in that trial of over 4,400 women,
radiologist reading ultrasound image data from SonoCine found cancers that were
50 percent smaller on average than the cancers found when reviewing mammography
alone. In addition, AWBUS has tripled the detection of cancers that are smaller
than 1 cm, which improves dramatically the prognosis of the patients. The
positive predictive value (PPV) for the biopsies resulting from the AWBUS exams
in this study was 38 percent(1) as compared to typical positive predictive
values for mammography alone of approximately 27 percent as reported by Halladay
et al in 2010.(2)


"Automated whole breast ultrasound is a major breakthrough in breast cancer
screening. It allows me to review breast imaging without the overlapping tissue
intrinsic to mammography. Compression of anatomy from various portions of the
breast can distort or even hide emerging cancers where AWBUS gives a slice by
slice presentation of the breast in a more natural appearance. It is
particularly effective in finding cancer in patients with dense breast tissue
when used in conjunction with mammography. Dense breast tissue is a key concern
as it is estimated that greater than 40 percent of the screening population have
focal dense or very dense breasts and past studies have shown mammography to be
least effective on dense breast tissue. AWBUS reaches that portion of the
population which is not well served by screening with mammography alone,"
commented Nathalie Duchesne, MD, of Head of Breast Imaging Division at Imagix
Medical Network, Breast Radiologist at Clinique Radiologique Audet and Director
of The Breast Practices. "The SonoCine System utilizes the ultrasound imaging
equipment that we already have in place at our practices. The early cancer
detection achievable with the SonoCine AWBUS examination is the result of a
number of important system characteristics. These include: recording of the
image data by a technologist for later review by a radiologist, automating and
computer controlling the screening of the entire breast and lower axillary lymph
nodes and maximizing lesion visualization and detectability by presenting the
recorded images in a cine format, thus allowing cancers to be identified by the
dynamic disruption of normal tissue architecture between frames. I have had the
great pleasure of reviewing it in use in the United States where it has been
available since 2008. Recent approval of the system combined with the convenient
fee plan enabled our breast center to immediately offer the procedure to our
patients. Currently, automated whole breast ultrasound screening is an optional
procedure which the patient may elect to have performed."


"Medipattern has been our collaborative software partner for many years.
Medipattern developed software for our image viewer and we worked together on
integrating B-CAD in our software," commented SonoCine founder Kevin Kelly, MD.
"They know our system well and can provide superb product support as well as
sales. Medipattern has a commitment to excellence that we have admired and
respected for years. We are pleased to be bringing the product to the Canadian
market through Medipattern."


"Medipattern was initially established to tackle identifying fast moving breast
cancer at an earlier stage. Medipattern developed one of the earliest whole
breast systems back in 2001, well before its time for market acceptance. For us,
working with SonoCine is a return to that goal. Our team developed a close
relationship with the SonoCine team during their product development phase.
Today, the market is well positioned and much more appreciative and receptive to
the benefits of whole breast ultrasound through SonoCine's dynamic automation
technology. Our understanding of the inherent technology used in the device
enables us to better support, sell and distribute SonoCine," commented Jeff
Collins, CEO of Medipattern. "AWBUS adds to our existing product line and
re-emphasizes our commitment to women's health. B-CAD has been shown to help
physicians better characterize breast lesions and under clinical study, reduce
the number of breast biopsies while still correctly identifying the cancers.(3)
Medipattern will receive commission on a per procedure basis for AWBUS which
will commence immediately following the first installation. We are actively
working with a dedicated group to establish breast centers in all of the
metropolitan cities in Canada using SonoCine. Broadening our women's health
product offering will add to revenue growth as we continue through calendar year
2012. In mid-April, the site in Quebec City will broadcast live cases via
satellite to The Breast Course 2012 in Lisbon, Portugal; where there will be
more than 325 participants from 42 countries. Dr. Duchesne is slated to speak
about the benefits of AWBUS at a poster session during the upcoming Canadian
Association of Radiologists (CAR) in April. Please visit www.sonocine.com to
learn more about this valuable service and hear what patients and doctors are
saying about the SonoCine System." 


(1) Kevin M. Kelly, MD, Judy Dean, MD, W. Scott Comulada, Sung-Jae Lee, "Breast
cancer detection: radiologists' performance using mammography with and without
automated whole-breast ultrasound" (http://sonocine.com/Reader_Study.pdf), Eur
Radiol (2010) 20: 2557-2564


(2) Halladay, Yankaskas, Bowling and Alexander, "Positive Predictive Value of
Mammography: Comparison of Interpretations of Screening and Diagnostic Images by
the Same Radiologist and by Different Radiologists" AJR Am J Roentgenol
(http://media3.marketwire.com/r/hayaboal). 2010 Sep; 195(3):782-5


(3) O'Donoghue, "Characterization by computer-aided detection (CAD) of breast
lesions imaged using ultrasound" (http://media3.marketwire.com/r/odonoghue)
Diagnostic Imaging Europe, August 2011


Upcoming Events



Annual Meeting - MHA             June 6 - 7, 2012            Brewster, MA   
SVU/SVS Annual Conference        June 7 - 9, 2012            Baltimore, MD  



About the SonoCine AWBU system and SonoCine, Inc: 

The SonoCine system was invented and engineered specifically for integration
with standard ultrasound scanners to provide radiologists with an effective,
systematic and automated screening examination for the early detection of
mammographically occult breast cancers in asymptomatic women. 


The high cancer detection performance reported by clinical users of SonoCine
AWBU is the result of a number of important system characteristics. These
include separating the image data acquisition from the radiologist's review,
automating and computer-controlling the screening of the entire breast and lower
axillary lymph nodes, and maximizing lesion visualization and detectability
using the company's proprietary dynamic review software. The risk-free procedure
is fully documented, quality-controlled and pain-free. 


Unlike mammography, the SonoCine AWBU procedure requires no breast compression
or x-ray radiation, and unlike MRI and MBI/BSGI, it requires neither a contrast
agent, nor a radioactive tracer.


Based in Reno, NV, SonoCine, Inc., is a privately owned research, development
and manufacturing company with focus on early breast cancer detection. 


About the Medipattern Corporation:

Medipattern(R) is a pioneer in the development of imaging software solutions
that help medical practitioners to better understand lesions and critical
anatomy. Medipattern uses its Cadenza(TM) technology to process images, finding
the salient region of interest and presenting them in 2D and 3D formats that
enhance the reader's perception. For more information, please visit the
Company's website: www.medipattern.com.


Medipattern(R) is a registered trademark of The Medipattern Corporation.
Cadenza(TM) is a trademark of the Medipattern Corporation. SonoCine(R) is a
registered trademark of SonoCine, Inc.


Forward-looking statements

This document contains forward-looking statements relating to Medipattern's
performance, operations, or business environment. These statements are based on
what we believe are reasonable assumptions given currently available information
and our understanding of Medipattern's current activities. We have tried,
whenever possible, to identify these forward-looking statements using words such
as "anticipates," "believes," "estimates," "expects," "plans," "intends,"
"potential," and similar expressions. Forward-looking statements are not
guarantees of future performance and involve risks and uncertainties that are
difficult to predict or control. A number of factors could cause actual outcomes
and results to differ materially from those expressed in forward-looking
statements. These factors include but are not limited to those set forth in the
Company's corporate filings (posted at www.sedar.com). In addition, these
forward-looking statements relate to the date on which they are made. The
Company disclaims any intention or obligation to update or revise any
forward-looking statements for any reason. Readers should not rely on
forward-looking statements.